Immunome (IMNM) Stock Forecast, Price Target & Predictions
IMNM Stock Forecast
Immunome stock forecast is as follows: an average price target of $30.33 (represents a 136.77% upside from IMNM’s last price of $12.81) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
IMNM Price Target
The average price target for Immunome (IMNM) is $30.33 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $23.00. This represents a potential 136.77% upside from IMNM's last price of $12.81.
IMNM Analyst Ratings
According to 4 Wall Street analysts, Immunome's rating consensus is 'Buy'. The analyst rating breakdown for IMNM stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Immunome Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Biren Amin | Piper Sandler | $23.00 | $12.64 | 81.96% | 79.55% |
| Apr 15, 2024 | Michael Schmidt | Guggenheim | $35.00 | $20.58 | 70.07% | 173.22% |
| Apr 01, 2024 | David Nierengarten | Wedbush | $33.00 | $24.68 | 33.71% | 157.61% |
The latest Immunome stock forecast, released on Aug 13, 2024 by Biren Amin from Piper Sandler, set a price target of $23.00, which represents a 81.96% increase from the stock price at the time of the forecast ($12.64), and a 79.55% increase from IMNM last price ($12.81).
Immunome Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $23.00 | $30.33 |
| Last Closing Price | $12.81 | $12.81 | $12.81 |
| Upside/Downside | -100.00% | 79.55% | 136.77% |
In the current month, the average price target of Immunome stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immunome's last price of $12.81. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 31, 2024 | Piper Sandler | - | Overweight | Initialise |
| Apr 15, 2024 | Guggenheim | - | Buy | Initialise |
| Apr 01, 2024 | Wedbush | Outperform | Outperform | Hold |
Immunome's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave IMNM a "Buy" rating, the same as its previous rate.
Immunome Financial Forecast
Immunome Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $19.79M | $15.65M | $10.86M | $6.81M | $3.30M | $589.10K | $2.36M | $2.36M | $2.36M | $2.36M | $2.36M | $2.36M | $2.90M | $2.20M | $1.87M | $2.80M | $2.07M | $2.10M | $390.50K |
| High Forecast | $19.79M | $15.65M | $10.86M | $6.81M | $3.30M | $589.10K | $2.36M | $2.36M | $2.36M | $2.36M | $2.36M | $2.36M | $2.90M | $2.93M | $1.87M | $2.80M | $2.07M | $2.10M | $390.50K |
| Low Forecast | $19.79M | $15.65M | $10.86M | $6.81M | $3.30M | $589.10K | $2.36M | $2.36M | $2.36M | $2.36M | $2.36M | $2.36M | $2.90M | $1.46M | $1.87M | $2.80M | $2.07M | $2.10M | $390.50K |
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Immunome's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMNM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Immunome EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.81M | $-8.19M |
| Avg Forecast | $11.88M | $9.39M | $6.52M | $4.08M | $1.98M | $353.46K | $1.42M | $1.42M | $1.42M | $1.42M | $1.42M | $1.42M | $1.74M | $1.32M | $1.12M | $1.68M | $1.24M | $1.26M | $234.30K |
| High Forecast | $11.88M | $9.39M | $6.52M | $4.08M | $1.98M | $353.46K | $1.42M | $1.42M | $1.42M | $1.42M | $1.42M | $1.42M | $1.74M | $1.76M | $1.12M | $1.68M | $1.24M | $1.26M | $234.30K |
| Low Forecast | $11.88M | $9.39M | $6.52M | $4.08M | $1.98M | $353.46K | $1.42M | $1.42M | $1.42M | $1.42M | $1.42M | $1.42M | $1.74M | $875.51K | $1.12M | $1.68M | $1.24M | $1.26M | $234.30K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.02% | -34.96% |
undefined analysts predict IMNM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immunome's previous annual EBITDA (undefined) of $NaN.
Immunome Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-4.07M | $-8.38M |
| Avg Forecast | $-44.92M | $-48.15M | $-54.30M | $-56.62M | $-58.50M | $-59.19M | $-59.23M | $-62.37M | $-49.72M | $-37.26M | $-36.12M | $-35.54M | $-31.94M | $-32.26M | $-22.74M | $-40.76M | $-16.38M | $-17.38M | $-22.78M |
| High Forecast | $-44.92M | $-48.15M | $-54.30M | $-56.62M | $-58.50M | $-59.19M | $-59.23M | $-62.37M | $-49.72M | $-37.26M | $-36.12M | $-35.54M | $-31.94M | $-28.50M | $-22.74M | $-40.76M | $-13.46M | $-17.38M | $-22.78M |
| Low Forecast | $-44.92M | $-48.15M | $-54.30M | $-56.62M | $-58.50M | $-59.19M | $-59.23M | $-62.37M | $-49.72M | $-37.26M | $-36.12M | $-35.54M | $-31.94M | $-41.40M | $-22.74M | $-40.76M | $-21.65M | $-17.38M | $-22.78M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.23% | 0.37% |
Immunome's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMNM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Immunome SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.24M | $1.17M |
| Avg Forecast | $21.39M | $16.91M | $11.73M | $7.35M | $3.56M | $636.50K | $2.55M | $2.55M | $2.55M | $2.55M | $2.55M | $2.55M | $3.14M | $2.37M | $2.02M | $3.03M | $2.23M | $2.27M | $421.92K |
| High Forecast | $21.39M | $16.91M | $11.73M | $7.35M | $3.56M | $636.50K | $2.55M | $2.55M | $2.55M | $2.55M | $2.55M | $2.55M | $3.14M | $3.17M | $2.02M | $3.03M | $2.23M | $2.27M | $421.92K |
| Low Forecast | $21.39M | $16.91M | $11.73M | $7.35M | $3.56M | $636.50K | $2.55M | $2.55M | $2.55M | $2.55M | $2.55M | $2.55M | $3.14M | $1.58M | $2.02M | $3.03M | $2.23M | $2.27M | $421.92K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 2.78% |
Immunome's average Quarter SG&A projection for Dec 23 is $2.23M, based on 1 Wall Street analysts, with a range of $2.23M to $2.23M. The forecast indicates a -0.23% fall compared to IMNM last annual SG&A of $2.24M (Dec 20).
Immunome EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.40 | $-0.90 |
| Avg Forecast | $-0.75 | $-0.80 | $-0.91 | $-0.94 | $-0.98 | $-0.99 | $-0.99 | $-1.04 | $-0.83 | $-0.62 | $-0.60 | $-0.59 | $-0.53 | $-0.54 | $-0.38 | $-0.68 | $-0.27 | $-0.29 | $-0.38 |
| High Forecast | $-0.75 | $-0.80 | $-0.91 | $-0.94 | $-0.98 | $-0.99 | $-0.99 | $-1.04 | $-0.83 | $-0.62 | $-0.60 | $-0.59 | $-0.53 | $-0.48 | $-0.38 | $-0.68 | $-0.22 | $-0.29 | $-0.38 |
| Low Forecast | $-0.75 | $-0.80 | $-0.91 | $-0.94 | $-0.98 | $-0.99 | $-0.99 | $-1.04 | $-0.83 | $-0.62 | $-0.60 | $-0.59 | $-0.53 | $-0.69 | $-0.38 | $-0.68 | $-0.36 | $-0.29 | $-0.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38% | 2.37% |
According to undefined Wall Street analysts, Immunome's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMNM previous annual EPS of $NaN (undefined).
Immunome Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.30 | $14.00 | 4566.67% | Buy |
| ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
| GANX | Gain Therapeutics | $2.07 | $7.00 | 238.16% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| ACRV | Acrivon Therapeutics | $7.85 | $22.00 | 180.25% | Buy |
| ANAB | AnaptysBio | $19.94 | $52.33 | 162.44% | Buy |
| RZLT | Rezolute | $5.44 | $13.50 | 148.16% | Buy |
| IMNM | Immunome | $12.81 | $30.33 | 136.77% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CELC | Celcuity | $15.36 | $31.50 | 105.08% | Buy |
| ADAG | Adagene | $3.05 | $5.00 | 63.93% | Buy |
| IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
IMNM Forecast FAQ
Is Immunome a good buy?
Yes, according to 4 Wall Street analysts, Immunome (IMNM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of IMNM's total ratings.
What is IMNM's price target?
Immunome (IMNM) average price target is $30.33 with a range of $23 to $35, implying a 136.77% from its last price of $12.81. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Immunome stock go up soon?
According to Wall Street analysts' prediction for IMNM stock, the company can go up by 136.77% (from the last price of $12.81 to the average price target of $30.33), up by 173.22% based on the highest stock price target, and up by 79.55% based on the lowest stock price target.
Can Immunome stock reach $20?
IMNM's average twelve months analyst stock price target of $30.33 supports the claim that Immunome can reach $20 in the near future.
What are Immunome's analysts' financial forecasts?
Immunome's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $8.61M (high $8.61M, low $8.61M), average EBITDA is $5.17M (high $5.17M, low $5.17M), average net income is $-239M (high $-239M, low $-239M), average SG&A $9.31M (high $9.31M, low $9.31M), and average EPS is $-3.992 (high $-3.992, low $-3.992). IMNM's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $53.11M (high $53.11M, low $53.11M), average EBITDA is $31.86M (high $31.86M, low $31.86M), average net income is $-204M (high $-204M, low $-204M), average SG&A $57.38M (high $57.38M, low $57.38M), and average EPS is $-3.403 (high $-3.403, low $-3.403).